Following an abbreviated submission, the Scottish Medicines Consortium (SMC) has accepted pramipexole dihydrochloride monohydrate prolonged release tablets (Mirapexin™) for use within NHS Scotland for the treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or “on off” fluctuations).

The drug advice notes that in patients for whom the use of pramipexole is appropriate, the prolonged-release formulation can provide the same daily dose as existing immediate release formulations, with the benefit of once-daily rather than thrice-daily dosing, at an equivalent cost.